Adage Capital Partners Gp, L.L.C. Eye Point Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51 Billion
- Q1 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 4,756,299 shares of EYPT stock, worth $41.4 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
4,756,299
Previous 4,466,420
6.49%
Holding current value
$41.4 Million
Previous $103 Million
4.75%
% of portfolio
0.19%
Previous 0.22%
Shares
8 transactions
Others Institutions Holding EYPT
# of Institutions
176Shares Held
53.9MCall Options Held
764KPut Options Held
1.57M-
Cormorant Asset Management, LP Boston, MA6.89MShares$60 Million8.2% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.76MShares$32.7 Million3.33% of portfolio
-
Franklin Resources Inc San Mateo, CA3.39MShares$29.5 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$24.3 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.47MShares$21.5 Million0.01% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $296M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...